A Phase II Study of Sorafenib Plus Tegafur/Uracil for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma.

Trial Profile

A Phase II Study of Sorafenib Plus Tegafur/Uracil for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 May 2015

At a glance

  • Drugs Sorafenib (Primary) ; Tegafur/uracil
  • Indications Liver cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 14 Jul 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
    • 14 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top